Skip to content
Sibutramine
Meridia (sibutramine) is a small molecule pharmaceutical. Sibutramine was first approved as Meridia on 1997-11-22. It is used to treat obesity in the USA. The pharmaceutical is active against sodium-dependent noradrenaline transporter and sodium-dependent dopamine transporter. In addition, it is known to target sodium-dependent serotonin transporter, cytochrome P450 2B6, and potassium voltage-gated channel subfamily D member 3.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nutritional and metabolic diseasesD009750
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Sibutramine hydrochloride
Tradename
Company
Number
Date
Products
MERIDIAAbbott BiotherapeuticsN-020632 DISCN1997-11-22
3 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
obesityEFO_0001073D009765E66.9
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A08: Antiobesity preparations, excl. diet products
— A08A: Antiobesity preparations, excl. diet products
— A08AA: Centrally acting antiobesity products
— A08AA10: Sibutramine
HCPCS
No data
Clinical
Clinical Trials
2 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
TineaD014005EFO_0007510B35.4——1——1
Tinea pedisD014008EFO_0007512B35.3——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Atopic dermatitisD003876EFO_0000274L20—1———1
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameSIBUTRAMINE
INNsibutramine
Description
Sibutramine is an organochlorine compound and a tertiary amino compound. It has a role as an anti-obesity agent and a serotonin uptake inhibitor.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(C)CC(N(C)C)C1(c2ccc(Cl)cc2)CCC1
Identifiers
PDB—
CAS-ID106650-56-0
RxCUI36514
ChEMBL IDCHEMBL1419
ChEBI ID9137
PubChem CID5210
DrugBankDB01105
UNII IDWV5EC51866 (ChemIDplus, GSRS)
Target
Agency Approved
SLC6A2
SLC6A2
SLC6A3
SLC6A3
Organism
Homo sapiens
Gene name
SLC6A2
Gene synonyms
NAT1, NET1, SLC6A5
NCBI Gene ID
6530
Protein name
sodium-dependent noradrenaline transporter
Protein synonyms
NET, neurotransmitter transporter, Norepinephrine transporter, solute carrier family 6 (neurotransmitter transporter), member 2, solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2, Solute carrier family 6 member 2, solute carrier family 6 member 5
Uniprot ID
Q96KH8
Mouse ortholog
Slc6a2 (20538)
sodium-dependent noradrenaline transporter (Q6QU62)
Alternate
SLC6A4
SLC6A4
CYP2B6
CYP2B6
KCND3
KCND3
Organism
Homo sapiens
Gene name
SLC6A4
Gene synonyms
HTT, SERT
NCBI Gene ID
6532
Protein name
sodium-dependent serotonin transporter
Protein synonyms
5-hydroxytryptamine (serotonin) transporter, 5HT transporter, 5HTT, Na+/Cl- dependent serotonin transporter, serotonin transporter 1, solute carrier family 6 (neurotransmitter transporter), member 4, solute carrier family 6 (neurotransmitter transporter, serotonin), member 4, Solute carrier family 6 member 4
Uniprot ID
Q5EE02
Mouse ortholog
Slc6a4 (15567)
sodium-dependent serotonin transporter (Q60857)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 3,110 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
48 adverse events reported
View more details